Hover over a term you want explained. If you need more details, then click on the term and a new tab will open with a full details page.
ANKTIVA (N-803) Plus BCG is a combined treatment for a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC). This cancer is found only in the inner lining of the bladder and has not spread into the muscle layer. BCG (bacillus Calmette-Guérin) is a standard treatment that uses a weakened form of bacteria to stimulate the immune system to attack bladder cancer cells. However, some patients’ cancers do not respond or stop responding to BCG alone, which is called BCG-unresponsive NMIBC. For these patients, ANKTIVA (N-803) is added to BCG. N-803 is an immune system booster known as an IL-15 superagonist, which helps activate immune cells more strongly. The combination is given directly into the bladder once a week for six weeks to help the body better fight the cancer.
When bladder cancer does not respond to BCG alone, treatment options have traditionally been limited and often involved surgery to remove the bladder (cystectomy). ANKTIVA (N-803) Plus BCG offers a newer option that can help many patients clear their cancer and avoid surgery. Clinical studies have shown promising results, with many patients experiencing complete cancer clearance and lasting effects for months or years. Most patients tolerate this treatment well, with side effects usually mild to moderate, such as bladder irritation or discomfort. It is an important option for patients and doctors seeking to manage BCG-unresponsive NMIBC with less invasive methods.
If you or a loved one is facing bladder cancer that has not responded to BCG, you might hear about ANKTIVA (N-803) Plus BCG during discussions about treatment options. Your care team may explain that this treatment is given directly into the bladder and aims to boost the immune system’s ability to fight cancer cells more effectively than BCG alone. You may see this term in your treatment plan, clinical notes, or educational materials. It is important to understand that while this treatment has shown good results, it may not work for everyone, and ongoing monitoring is needed to watch for any return or progression of cancer.
ANKTIVA (N-803) Plus BCG may appear in your medical records, treatment plans, or discussions about clinical trials. It might also be mentioned in drug information sheets or educational materials provided by your healthcare team. Sometimes it is referred to by other names such as N-803 or Nogapendekin alfa inbakicept, so comparing terms can help avoid confusion.
Hearing about ANKTIVA (N-803) Plus BCG does not mean the cancer is cured or that surgery will be avoided for sure. It is an option to try when BCG alone has not worked, but it does not guarantee success. It is also not an experimental or unproven treatment—it has been approved by the U.S. Food and Drug Administration (FDA) for certain patients—but it may not be suitable for everyone.
If this treatment is mentioned, you might ask about how it compares to other options, what side effects to expect, and how long the treatment lasts. You can also ask about the goals of treatment, possible benefits and risks, and what follow-up will involve. Understanding all your treatment choices helps you feel more confident and supported in your care journey.
This information is educational and does not replace personalized medical advice. Your healthcare provider can help determine if ANKTIVA (N-803) Plus BCG is appropriate for your specific situation. The next sensible step if you or a loved one has BCG-unresponsive NMIBC is to discuss with your urologist or oncologist whether this treatment might be an option. They can explain the potential benefits and risks, how the treatment is given, and what monitoring will be needed.
Public source information used for this glossary entry includes: